Overview of Ostenil Plus

Quick Facts

Property	Description
Active ingredient	Sodium Hyaluronate (a salt of Hyaluronic acid)
Form	Sterile solution for single-dose intra-articular injection
Pharmacological class	Viscosupplementation agent
General purpose	Restoration of joint fluid viscoelasticity
Origin	Biologically derived (via bacterial fermentation)

Ostenil Plus is a highly purified, single-ingredient orthopedic injection classified as a viscosupplementation agent. The product is administered as a sterile, high-viscosity solution for intra-articular injection, intended to restore the essential mechanical functions of the fluid within a joint.

What Class of Medicine is Ostenil Plus?

Ostenil Plus belongs to the therapeutic class of viscosupplementation agents, a non-pharmacological category of treatments aimed at mechanically augmenting the joint environment. It is typically regulated as a medical device. This classification signifies that its mechanism of action is primarily mechanical, acting as a joint fluid supplement rather than functioning as a systemic drug. This localized, mechanical approach is clinically recognized for providing support in joints where the natural fluid has degraded.

What is the Composition and Origin of Ostenil Plus?

The core active ingredient is Sodium Hyaluronate, the salt form of Hyaluronic acid (HA), a large molecule that naturally occurs in connective tissues throughout the body. Ostenil Plus is differentiated by its use of a specific high molecular weight formulation, which is critical for restoring optimal fluid viscoelasticity. The product is manufactured using bacterial fermentation, a process that ensures a highly purified, non-animal natural origin, reducing the potential for adverse immune responses. This purity allows for the product's positioning as a single-dose injectable solution.

What is the General Purpose of Viscosupplementation?

The fundamental purpose of this therapy is to improve the joint's function by restoring the fluid's viscoelasticity—its ability to function both as a thick fluid (lubrication) and an elastic cushion (shock absorption). Supplementation provides benefits beyond its basic mechanical role. This support offers chondroprotection and helps facilitate smoother, unimpaired motion, which is a typical benefit for individuals seeking to maintain mobility.

Regulatory References

Viscosupplementation for Knee Osteoarthritis: A Review of Clinical and Cost-Effectiveness and Guidelines - NCBI Bookshelf

What side effects are possible with Ostenil Plus?

Possible Side Effects and Safety Information

The safety profile for Ostenil Plus, consistent with other intra-articular sodium hyaluronate products, is focused on localized reactions at the injection site, reflecting its non-systemic, mechanical action as a viscosupplementation agent. Adverse effects are officially classified within the Musculoskeletal and Connective Tissue Disorders and General Disorders and Administration Site Conditions System-Organ Classes.

Regulatory Classification of Adverse Reactions

The most frequently documented adverse reactions are common and generally transient (self-limiting), associated with the injection procedure itself. These include arthralgia (joint pain or discomfort), injection-site pain, swelling, and temporary joint stiffness.

Uncommon documented effects may involve localized signs like redness (erythema) or joint effusion (excess fluid buildup).

Serious Adverse Reactions and Safety Restrictions

Serious adverse reactions are classified as rare but include joint infection (septic arthritis), which is a procedural risk of any intra-articular injection, and severe hypersensitivity reactions (allergic-type responses).

The product is contraindicated and should not be administered into a joint with active infection or severe inflammation. Likewise, use is excluded if skin diseases or infections are present at the intended injection site.

Safety documentation for this class of treatment notes that use in pregnant or lactating women and children is not recommended due to a lack of adequately studied clinical evidence in these specific populations.

Overdose and Emergency Response

Overdose and when to seek help

Due to the product's classification as a locally-acting viscosupplementation agent administered by intra-articular injection, official regulatory documentation does not define a specific systemic overdose syndrome.

Over-administration, or local incompatibility reactions, may manifest as localized phenomena at the injection site. These documented signs include pain, swelling, a feeling of heat, redness, joint effusion, and pruritus. Management of these localized effects relies on standard symptomatic and supportive treatment. No specific antidote is documented for the product.

When to Seek Immediate Medical Help

Immediate medical attention is officially required for any severe or rapidly developing symptoms. The most critical concerns are related to the invasive injection procedure itself, rather than the Sodium Hyaluronate solution.

Regulatory documents list very rare systemic effects of the procedure that constitute a serious incident. These include signs such as tachycardia (rapid heart rate), hypotension (low blood pressure), and shortness of breath. Additionally, severe joint infection is a documented, very rare risk associated with all invasive joint treatments, and any suspicion mandates urgent professional care.

Hospital monitoring or close clinical observation may be required for managing these serious systemic reactions or a suspected severe infection. Official labeling also states that the product is not recommended for use in children, pregnant, or lactating women due to the absence of specific clinical evidence in these populations.

Therapeutic Uses of Ostenil Plus

What Ostenil Plus Treats: Main Uses and Benefits

The primary use of this treatment is within the therapeutic domain of managing symptoms associated with physical discomfort in situations involving conditions characterized by periods of heightened symptoms. This category of treatment is commonly used to help with the management of localized discomfort.

Ostenil Plus is generally applied across domains where additional symptomatic support is needed, and may assist with symptoms related to physical discomfort that interfere with daily functioning. This is relevant in contexts involving localized discomfort or tension, which includes use for general joint-related pain and stiffness. The treatment is considered useful in conditions involving episodic or fluctuating manifestations, helping manage symptom clusters that may become intense or disruptive.

“It provides support that helps ease the overall symptom burden, which is relevant when short-term symptomatic assistance is needed.”

This use may assist with maintaining functional stability, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations during phases when symptoms become more noticeble.

Quick Fact: Support for Joint Discomfort

Regulatory References

FDA Summary of Safety and Effectiveness Data

Eligibility and Restrictions for Use

The eligibility profile for Ostenil Plus is strictly defined by regulatory documents, which outline the populations allowed to use the product and those who are formally excluded or not recommended. The injection is indicated for use in adult patients experiencing pain and restricted mobility in the knee and other large synovial joints.

Absolute Contraindications

Use is strictly contraindicated (prohibited) for any patient who has an ascertained hypersensitivity or allergy to any of the constituents contained in the product formulation.

Populations Not Recommended (Lack of Clinical Data)

The official label states that treatment is not recommended in several key groups due to an established lack of clinical evidence on the use of hyaluronic acid in these populations:

Age: Children.
Life Stages: Pregnant women and lactating women (breastfeeding).
Comorbidities: Patients with inflammatory joint diseases, including rheumatoid arthritis or Ankylosing Spondylitis (Bechterew disease).

Conditional Eligibility

Regulatory guidance specifies that if there is existing joint effusion (excess fluid or swelling), the effusion must be reduced first before the product can be administered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory information for Ostenil Plus, which is a localized viscosupplementation agent, focuses primarily on local chemical and procedural constraints rather than systemic drug interactions.

Official Interaction Statements

Interaction Type	Restriction or Requirement	Basis in Regulatory Labeling
Prohibited Combination	Disinfectants containing quaternary ammonium salts must not be used concurrently for skin preparation.	Physicochemical incompatibility; these substances cause the precipitation of sodium hyaluronate.
Sequential Administration	If a joint effusion is treated with an intra-articular corticosteroid injection, Ostenil Plus treatment should be started two to three days later.	Mandatory timing separation rule for sequential procedures.
Intra-Articular Solutions	No information is available regarding incompatibility with other solutions intended for intra-articular use.	Undocumented compatibility; formal regulatory data is absent.

Absence of Systemic Interactions

Due to the product's localized, non-systemic nature, official regulatory labeling does not document any interactions related to systemic metabolic enzymes (such as CYP450), drug transporters (such as P-gp), food, alcohol, or herbal products. The interaction profile is solely constrained by the requirements for safe and effective local administration within the joint.

Mechanism of Action

Viscoelastic Restoration and Friction Modulation

This mechanism is the core physical action, where the high-molecular-weight Sodium Hyaluronate directly restores the degraded viscoelasticity of the synovial fluid within the joint space. By functioning as both a lubricant and a shock absorber, the substance immediately normalizes joint biomechanics, thereby reducing friction between articular surfaces and decreasing local mechanical activation of nerve endings.

Cellular Signaling and Anti-Catabolic Action

Beyond the physical effect, the high-molecular-weight molecule acts as a biological modulator, engaging receptors like CD44 on joint cells (synoviocytes and chondrocytes). This interaction suppresses the cellular synthesis and activity of destructive catabolic enzymes (MMPs and ADAMTS) that degrade the cartilage matrix. This mechanism simultaneously stimulates the synoviocytes to increase their endogenous production of high-quality Hyaluronic Acid, facilitating the establishment of a balanced local cellular environment.

️ Stabilization of the Mechanism via Scavenging

The mechanism's duration is influenced by the inclusion of Mannitol, which provides a synergistic stabilization mechanism. Mannitol functions as a potent free radical scavenger, chemically neutralizing Reactive Oxygen Species (ROS) abundant in inflamed environments. This action prevents the rapid oxidative breakdown (depolymerisation) of the Sodium Hyaluronate chains, ensuring the molecule maintains its full viscoelastic properties and cellular signaling ability, influencing its residence time.

Dosage and Administration Information

How to Use Ostenil Plus

This section details the official administration guidelines for Ostenil Plus.

Instruction	Detail
Route of Administration	Intra-articular injection (directly into the joint cavity).
Dosing Schedule	40 mg of sodium hyaluronate in a 2.0 ml volume per injection.
Frequency and Schedule	Typically administered once a week for a course of 1 to 3 total injections.
Preparation Requirements	Packaged as a sterile, single-dose pre-filled syringe; any unused solution must be discarded.
Age-Group Administration Rules	Not recommended for use in children or in pregnant and lactating women.
Special Procedural Conditions	Administration must be performed by a physician or qualified clinician; any existing joint effusion (swelling) must be reduced prior to injection.

Instruction Classifications (High-level)

The administration is classified as a localized injection that follows an intermittent, structured course. Official use is contingent upon the expertise of a clinician and the necessary pre-treatment condition of the joint.

Resulting Procedural Structure

Official step sequence:

Confirm treatment course consists of 1 to 3 weekly injections into the affected synovial joint.
Prior to the injection, reduce any significant joint effusion present.
The 40 mg/2.0 ml dose is administered intra-articularly by a clinician.
Repeat treatment cycles may be administered as required when the symptomatic support wears off, which may occur six months or longer after the previous course.

Connection to the overall use protocol (2–4 sentences):

The instructions establish a definitive protocol where the product is used through a physician-administered, intra-articular injection performed according to a low-frequency, short-term schedule. This structure defines the use of a precise dose directly at the site of application and mandates specific pre-injection conditions, ensuring a standardized procedural approach.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ostenil Plus

This section describes the research available for the product class.

Evidence for use in Symptomatic Joint Discomfort (Osteoarthritis)

Research has explored the use of this viscosupplementation class in patients dealing with conditions characterized by fluctuating or episodic manifestations, primarily symptomatic osteoarthritis of the knee and hip. The research base includes Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-Analyses.

Studies examined outcomes related to physical discomfort and daily functioning or activity level in adult populations. Findings describe patterns observed where patient-reported pain intensity and functional capacity evolved during observation periods, typically up to six months. The overall certainty regarding long-term outcomes remains low across the class of treatments.

Outcomes Evaluated in Clinical Trials

The research examined what patients experienced by measuring specific patient-reported outcomes describing perceived discomfort. These trials utilized standardized indices, such as the WOMAC and VAS scales, which help researchers track changes in reported pain, physical function, and joint stiffness. Research also explored how the use of concurrent rescue pain medication was monitored during the study period.

Comparing Ostenil Plus in the Context of Viscosupplementation

This section examines the data showing patterns related to the high molecular weight sodium hyaluronate class, including studies where it was evaluated against other substances. Evidence suggests that patterns were observed in patient-reported outcomes when compared to an inactive control in some systematic reviews. However, findings were mixed across the entire class of viscosupplementation treatments. This contributes to the acknowledged inconsistency in treatment recommendations issued by different international clinical guideline bodies.

Long-term Studies and Durability of Response

Studies primarily focused on research exploring short-term symptom changes, with key RCTs having follow-up durations generally limited to a maximum of six months (24 weeks). Long-term effects are not fully established from controlled trial settings. There is limited information from controlled trials that definitively describe the persistence or durability of response over periods exceeding one year.

Research in Specific Patient Groups

The main body of evidence was studied for symptomatic osteoarthritis in the general adult population. Data for certain groups remain insufficient, including for specific patient subgroups with severe co-existing medical conditions or very advanced joint degeneration. The study results reflect the specific conditions and patient profiles under which they were conducted.

What Remains Uncertain in the Research Landscape

The overall evidence quality varies across studies for the entire class of viscosupplements. Key limitations include limited follow-up durations and the lack of comprehensive comparative evidence against all available treatment options. The research provides context but does not offer individual predictions, and the evidence highlights what is known—and what is still uncertain—about this treatment approach.

Frequently Asked Questions (FAQ)

Common questions about Ostenil Plus (FAQ)

Q: What is the main difference between Ostenil and Ostenil Plus?

Official labeling indicates that the two products have different compositions. Ostenil Plus contains a higher concentration of sodium hyaluronate. Additionally, it includes the ingredient mannitol, which is not present in the standard Ostenil product. This difference in composition supports the product's specific administration schedule.

Q: How quickly should I expect to feel any difference after the injection?

According to official product documentation, the expected symptomatic improvement is not immediate. The beneficial effects of the treatment are described as gradual in nature. Individuals may begin to notice a difference in pain and mobility over the following few weeks after the injection is administered.

Q: Why is the number of required injections lower for Ostenil Plus compared to other hyaluronic acid products?

The formulation is defined by its composition: a higher concentration of sodium hyaluronate and the addition of mannitol. This composition is the rationale provided for the product’s specific administration schedule, which typically involves a lower number of total injections per course.

Q: What ingredients are in Ostenil Plus besides hyaluronic acid?

The core component is sodium hyaluronate. The full composition of the isotonic solution also includes mannitol, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, and water for injections. These ingredients contribute to the product's isotonic solution and stability.

Q: How is Ostenil Plus different from a cortisone or steroid injection?

Official classification documents describe this product as a viscosupplementation agent, which is typically regulated as a medical device. Its primary action is mechanical, designed to restore joint fluid properties. This differs from corticosteroids (steroids), which are pharmacological agents used specifically to treat inflammation.

Q: What clinical trials support the use of Ostenil Plus?

The use of the product is supported by clinical research, including controlled trials that examine patient outcomes compared to other treatments. Specific trial information is registered in public regulatory databases, such as ClinicalTrials.gov.

Q: Can I take my regular painkillers or anti-inflammatories before or after the injection?

Official regulatory documentation states that no information is currently available regarding the incompatibility of the product with oral analgesic (painkiller) or anti-inflammatory medicines. The only specific constraint is a mandatory timing separation rule if a concurrent intra-articular corticosteroid is used.

Q: Do I need to stop any of my medications before getting the injection?

Official labeling only provides a mandatory timing separation rule regarding prior treatment with an intra-articular corticosteroid injection, requiring two to three days between procedures. Official labeling for the product class does not document specific requirements to stop systemic medications before the procedure.

Q: Is it possible for the injection not to have any noticeable effect?

A lack of improvement or no response to the injection is noted in clinical information as a potential outcome. This reflects the variability observed across treatments in this class, and the effectiveness is not guaranteed for every individual.

Q: Are there any long-term safety concerns documented for repeated use?

Official product information indicates that repeat treatment cycles may be administered as required when the symptomatic support wears off. Repeated courses are supported by safety profiles when administered correctly according to the official guidelines.

Q: Can I drive immediately after getting the injection?

Official patient instructions recommend avoiding strenuous activities or heavy strain on the joint for up to 48 hours following the procedure. The decision to resume activities like driving is a matter of clinical discretion based on the individual’s condition and the procedure.

Q: How long do I need to rest or limit activity after the procedure?

Patient instructions generally advise against putting heavy strain on the treated joint or engaging in strenuous activities for approximately 48 hours after the injection. Following this initial period, individuals may generally resume their normal, low-impact activities.

Q: Is there a maximum number of times you can have this treatment in your lifetime?

Official documentation indicates that repeat treatment cycles may be administered as required when symptoms return. There is no official maximum limit stated in the labeling for the number of lifetime treatments.

Q: What should I do if the injection site becomes warm or very swollen a few days later?

Unexpected or worsening symptoms at the injection site may require clinical evaluation by a physician. The official guidance notes that if the area develops unexpected pain, warmth, redness, or swelling that persists or worsens, clinical consultation is necessary.

Q: Are there any specific activities that are forbidden after the injection?

Patient information outlines the need to avoid strenuous activities that place heavy strain on the joint during the initial 48 hours following the procedure. Examples include jogging, heavy lifting, or playing sports like soccer or tennis.

Q: Can the injection be administered in both knees at the same time?

Official instructions indicate that several joints may be treated at the same time. This allows for the injection to be administered to both affected joints during the same appointment, provided the full administration procedure is followed for each joint.

Q: What is the official definition of the severity of osteoarthritis that Ostenil Plus is used for?

The official indication for the product is based on the presence of pain and restricted mobility in the affected joint due to osteoarthritis. The labeling focuses on symptomatic use and does not formally reference a specific classification of radiographic severity, such as a Kellgren-Lawrence grade.

Q: What if I experience unusual side effects not listed on the official leaflet?

The documented procedure for reporting a serious or unexpected side effect involves notifying the manufacturer and the local competent authority (the governmental body) overseeing medical device safety. This ensures the ongoing safety monitoring of the product.

Q: Is Ostenil Plus used in combination with physical therapy?

The product is frequently described as part of a conservative and comprehensive approach to managing joint symptoms. This overall approach may involve the use of other non-pharmacological treatments, such as physical therapy and lifestyle adjustments.

How should Ostenil Plus be stored and disposed of?

Storage Conditions

The pre-filled syringe of Ostenil Plus must be stored within a temperature range between 2, C and 25, C and kept out of the reach of children. The product must not be used after the expiry date indicated on the box. Storage must maintain the product's integrity: the contents and outer surface are sterile as long as the sterile pack remains unbroken.

Handling and Stability

The solution is strictly for single use only. Any solution not used immediately after opening must be discarded because the product's sterility is no longer guaranteed, which is associated with a potential risk of infection. The product must not be resterilized.

Disposal Instructions

Due to its classification as a medical sharp, the used syringe must be placed immediately in a sharps disposal container. The pre-filled syringe and any unused contents must not be thrown away in the household trash. Users are required to follow their community guidelines for the safe disposal of the sharps container.

Ostenil Plus